- Email: [email protected]
MS and application to a pharmacokinetic study in healthy volunteers
Journal Pre-proofs Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers Yingyue Yi, Guanghui Ren, Ming Zheng, Di Zhao, Ning Li, Xijng Chen, Yang Lu PII: DOI: Reference:
S1570-0232(19)31662-9 https://doi.org/10.1016/j.jchromb.2019.121955 CHROMB 121955
To appear in:
Journal of Chromatography B
Received Date: Revised Date: Accepted Date:
14 November 2019 17 December 2019 19 December 2019
Please cite this article as: Y. Yi, G. Ren, M. Zheng, D. Zhao, N. Li, X. Chen, Y. Lu, Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers, Journal of Chromatography B (2019), doi: https://doi.org/10.1016/ j.jchromb.2019.121955
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2019 Published by Elsevier B.V.
Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers Yingyue Yia,#, Guanghui Rena,#, Ming Zhengc, Di Zhaoa, Ning Lib , Xijng Chena, *1, Yang Lua, *2 a
Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province 211198, China. b National Experimental Teaching Demonstration Center of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China. c School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 100 Kexue, Zhengzhou 450001, China #These authors contributed equally to the present work.
1
*Corresponding author at: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing 211198, China. E-mail address: [email protected]. 2 *Corresponding author at: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing 211198, China. E-mail address: [email protected]
Abstract JJH201501, a deuterated modification for multi-target antidepressant vortioxetine, is currently in phase I clinical trial. This study aimed to establish a sensitive and rapid UPLC-MS/MS method that was capable of simultaneously detecting JJH201501 and its major metabolite JJH201501-01 quantitatively in human plasma. The pretreatment was achieved by protein precipitation using 4-fold(v:v) acetonitrile with 0.05 ng/mL fluoxetine as internal standard precipitant. For method validation, the method was investigated in terms of the selectivity, inter- and intra-run precision and accuracy, matrix effect, extraction recovery and stability. The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively. The linear concentration range for JJH201501 and JJH201501-01 was 0.2 to 50 ng/mL and 0.4 to 100 ng/mL, respectively. The results showed that this method was in line with the guidelines for bioanalytical method proposed by FDA. In addition, the method was successfully applied to a plasma pharmacokinetic study of JJH201501 tablets in healthy volunteers which was part of the phase I trial.
Keywords: Deuterated modification; Vortioxetine; UPLC-MS/MS; Antidepressant; Healthy volunteers
1.Introduction Vortioxetine, a multi-target antidepressant drug, was approved by the FDA in 2013 [1], and changed its brand name from Brintellix to Trintellix in 2016 [2]. It was first synthesized and reported by Benny Bang-Andersen et al.[3]. Different from traditional antidepressants, vortioxetine exerted its efficiency through modulation of human serotonin receptors and inhibition of serotonin transporters (Ki=1.6 nM)[4]. Vortioxetine can increase the DA (dopamine), NA (noradrenaline) and 5-HT (5-hydroxytryptamine) levels in the medial prefrontal cortex and ventral hippocampus of rats. It is also effective in patients with major depressive disorder and can reduce the risk of relapse after remission of depression treatment
[5]
. Recent studies show that after treatment with
vortioxetine there is a significant alleviation for both insomnia and depressive symptoms in severe depressive disorder patients with insomnia[6]. In addition to antidepression, vortioxetine also exhibits an immunomodulatory activity[7]. In terms of pharmacokinetics, the two-compartment model fitted the concentration-time curve of vortioxetine in humans plasma to a great extent [8]. The average elimination half-life of vortioxetine in human is 66 h and the oral bioavailability reaches 75% [9].
Deuteration is defined as the process of replacing the hydrogen element in a molecule with deuterium. The strength of the C-2H bond is greater than that of the C-1H bond[10, 11]
, which results in the altered reaction rate of breaking C-2H bond during the
metabolism of the deuterated drug. The reaction rate might vary by a factor of 6 to 10 with the increase of deuterium-replacement[10]. Deuteration could reduce drug
elimination catalyzed by metabolic enzyme and the formation of toxic metabolites[12] via increasing the difficulty of decomposition of the C-2H band, thereby ameliorating some properties of the drug. In 2017, US FDA approved the first deuterated drugdeutetrabenazine from Teva Pharmaceuticals for the treatment of Huntington's disease [13]
. In addition, there are many other deuterated drugs in development stage. Compared
with the original drug, the deuterated modification could alter the drug metabolism and reduce toxicity[14-17].With the basis of the original drug, the development of deuterated drug possesses an advantage of convenience over new chemical entity [12].There will be a promising future for deuterated drugs[18].
JJH201501 was a deuterated modification of vortioxetine (structure shown in Fig 1). After intragastric administration in rats, JJH201501 was mainly excreted through feces and urine in forms of metabolites. JJH201501-01 was the main metabolite of JJH201501 in vivo and closely related to the metabolism of JJH201501. Currently, JJH201501 is in phase I clinical trial. This present study aimed to establish a sensitive and rapid UPLC-MS/MS (ultra-performance liquid chromatography-tandem mass spectrometry) determination method to quantify JJH201501 and JJH201501-01 simultaneously, which can provide assistance and reference for the follow-up investigation. 2. Material and method 2.1 Chemicals and reagents The reference standards of JJH201501 and JJH2015-01 were provided by Jiangsu
Jiberer Pharmaceutical Co., Ltd. (Jiangsu，China). Fluoxetine (used as internal standard, IS) was purchased from National Institutes of Food and Drug Control (Beijing, China). The HPLC-grade acetonitrile and methanol were purchased from Merck & Co., Inc (Germany). Ammonium acetate and formic acid of HPLC grade were purchased from Macklin Inc (Shanghai, China) and Shanghai Aladdin Bio-Chem Technology Co., LTD (Shanghai, China), respectively. Ultrapure water was purified by a Milli-Q Reagent Water System (Millipore, Bedford, MA, USA).
2.2 UPLC-MS/MS condition The separation of compounds was performed by ACQUITY UPLC system (Waters Corp., Milford, MA, USA), incorporating a Shim-pack GISS C18 column (2.1 mm × 50 mm, 1.9 μm). The column oven was set at 50℃. The gradient elution solvents were consisted of 0.1% formic acid aqueous solution (A) and acetonitrile (B), and the gradient procedure was set as follow: 0-0.5 min, 20%-95% B; 0.5-1.9 min, 95% B; 2.0– 3.0 min, 20% B. The flow rate was 0.50 mL/min. The total run time was 3 min. Quantification was performed by Triple QuadTM 6500+ Mass Spectrometer with Analyst 1.7.1 software package (AB SCIEX LLC., Redwood City, CA, USA), using positive-mode electrospray ionization (ESI) interface. Multiple-reaction monitoringmode was applied. Quantification was achieved by transitions of m/z 302.2→149.9, m/z 329.1→286.1 and m/z 310.1→44 for JJH201501, JJH201501-01 and fluoxetine (IS), respectively. The optimal instrument conditions were as follows: curtain gas, gas 1 and gas 2 (nitrogen) were 40, 55 and 55 psi respectively; collision gas was 8 psi; dwell
time was 200 ms; source temperature was 600 ℃; Ion spray voltage was 5500 V. Declustering potentials (DP) and collision energy (CE) were shown in Table 1.
2.3 Sample preparation 2.3.1 Preparation of stock and working solution Stock solutions of JJH201501, JJH2015-01, fluoxetine (IS) were separately prepared by dissolving the reference standard in methanol at the concentration of 1.0 mg/mL and stored at 2-8℃. Mixed standard working solutions of JJH201501 and JJH2015-01 were prepared by diluting the mixed solution 1 (JJH201501:1000 ng/mL; JJH2015-01:2000 ng/mL) with methanol to the JJH201501 concentrations of 4, 10, 20, 40, 100, 200, 400 ng/mL and JJH201501-01 concentrations of 8, 20, 40, 80, 200, 400, 800 ng/mL. The mixed quality control (QC) solutions were prepared from the mixed solution with same concentration as mixed solution 1, in which JJH201501 concentrations were 4 (LLOQ, lower limit of quantitation), 12 (LQC, low quality control), 80 (MQC, medium quality control), and 800 (HQC, high quality control) ng/mL and JJH201501-01 concentrations were 8, 24, 160, 1600 ng/mL, respectively. Fluoxetine (IS) working solution was prepared by diluting the stock solution with acetonitrile to 1 ng/mL. All working solutions were stored at 2-8℃.
2.3.2 Preparation of calibration and QC samples Calibration and QC samples were prepared by mixing 20 μL of corresponding working
solutions with 380 μL blank human plasma. The final calibration curve included following concentration points: 0.2, 0.5, 1, 2, 5, 10, 20, 50 ng/mL for JJH201501 and 0.4, 1, 2, 4, 10, 20, 40, 100 ng/mL for JJH2015-01. Mixed QC samples were consisted of LLOQ, LQC, MQC and HQC samples. The respective JJH201501 concentration was 0.2, 0.6, 4 and 40 ng/mL. The IS working solutions were diluted with 19 folds (v:v) acetonitrile to get internal standard precipitant.
2.3.3 Sample preparation 200 μL of internal standard precipitant was added into 50 μL thawed plasma samples for protein precipitation, and then the sample was vortex-mixed for 5 min. Subsequently, the fully blended mixtures were centrifuged at 18000 g for 10 min and 80 μL of the supernatant was transferred into auto-sampler vial, 1 μL of which was injected into the UPLC-MS/MS system for analysis.
2.4 Method validation The analytical method was validated in accordance with the guidelines proposed by US FDA in the following aspects: selectivity, linearity and lower limit of quantification, accuracy and precision, carryover, matrix effect and extraction recovery, stability.
2.4.1 Selectivity Blank human plasma from six different volunteers was employed to validate the selectivity of the method to see if there was any background interference for analytes
and IS. Simultaneously, LLOQ (lower limit of quantification) samples, the lowest point of the calibration curve whose signal-to-noise ratio (S/N) >10, was prepared as control. According to the guideline, the response intensity appearing at the retention time of analytes and IS should be less than 20% and 5% of response intensity in LLOQ, separately.
2.4.2 Linearity and LLOQ Linearity of the method was evaluated, based on the standard calibration curve. A batch of standard calibration curve samples were consisted of double blank (blank plasma with pure precipitant, acetonitrile in this case), zero-point sample (blank plasma with internal standard precipitant) and eight gradient calibration samples. Double calibration standard curves were employed which were placed respectively at the beginning and end of an analytical batch. To obtain the calibration curve, firstly the peak area ratios (y) of each analyte to IS was plotted against the theoretical concentrations (x) and then the weighted least-squares linear regression(1/x2) was made to get the regression line and equation. The sensitivity investigation was based on lower limit of quantitation (LLOQ), which should be within ± 20% for accuracy (relative error, RE, %), while RE of other points on the standard calibration curve should be within ± 15% for accuracy.
2.4.3 Accuracy and precision The intra- and inter-run accuracy and precision were evaluated as the variation of QC
samples. For investigation of intra run accuracy and precision, six replicate QC samples at each concentration, namely, LLOQ, LQC, MQC, HQC (n=6) were analyzed in the same analytical batch while the inter-run counterpart was evaluated between three analytical batch. The accuracy was calculated as the RE of each sample and the precision was determined as RSD of six replicates at the same concentration. According to the guideline, the intra- and inter-run accuracy was supposed to be within ± 15% while that of LLOQ should be within ± 20%. The precision should be within ± 15% (for LLOQ, within ± 20%). 2.4.4 Carryover Carryover was evaluated by residual response arose from the upper limit of quantification (ULOQ), the highest point on the calibration curve. There was a double blank sample after injection of ULOQ in the same run to investigate the carryover. The response intensity in the blank sample was not supposed to exceed 20% of the LLOQ of the analytes, and 5% of the IS. 2.4.5 Matrix effect and extraction recovery The matrix effect and extraction recovery were evaluated by comparing pure solution QC samples, unextracted QC samples and post-extracted QC samples. Pure solution QC samples (n=6) were consisted of 10 μL QC solution, 40 μL IS working solution, 190 μL physiological saline and 760 μL acetonitrile while unextracted QC samples (n=6) were made by combination of 10 μL QC solutions, 40 μL IS working solution and 950 μL post-extracted matrix. Three different types of matrix were investigated, including blank plasma, hemolyzed matrix and high fat matrix. Post-extracted QC samples (n=6)
were prepared by the method shown in 2.3.3. 2.4.6 Stability The stability of the analytes plasma samples was evaluated by LQC (n=6) and HQC (n=6) samples placed under different conditions: room temperature (25℃) for 22 h; −20 ℃ for 6 days; −70 ℃ for 56 days; five freeze (−70℃)-thaw (25℃) cycles; and processedsamples at auto-sampler vials (8 ℃) for 24 h. The RE of plasma samples under different condition to fresh plasma sample should be within 15%, and the CV (%) should be below 15%.
2.5 Application in the JJH201501 pharmacokinetic study The clinical trial was approved by the China Food and Drug Administration (No. 2018L02861). The whole study was carried out in accordance with the chemical drug clinical pharmacokinetic study technical guidelines of China and the Declaration of Helsinki. Before the study, the Informed Consent Form was reviewed and signed by every enrolled subject.
Twelve adult healthy volunteers were enrolled, including 6 males and 6 females. They were randomly assigned into JJH201501 group (10 volunteers) and placebo group (2 volunteers). All volunteers were aged between 18–45 years; the male volunteers were weighed beyond 50 kg, while the female volunteers were beyond 45 kg; the body mass indexes (BMI) of all volunteers were between 18-26 kg/m2. Volunteers were administrated with JJH201501 tablet under fasting state at an oral dose
of 10 mg/kg. Blood samples were collected 1 h pre-administration and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 240 h post-administration. Blood samples were placed in heparinized centrifugal tubes, subsequently centrifuged at 3075 g for 10 min at 4 °C (blood sample collection was completed within 1 h), and the separated plasma was stored at -70 ± 10 °C before analysis. 3. Results and discussion 3.1. Method development To choose the internal standard, several compounds including vortioxetine-D8 and fluoxetine were investigated. Vortioxetine-D8 showed interference to the peak of JJH201501. The structure of fluoxetine was similar to that of JJH201501 and its retention time is close to JJH201501 without any inference to the peak of JJH201501. Thus, fluoxetine was selected as the internal standard. In the process of establishing chromatography method, the ACQUITY UPLC
®
BEH
C18 column and Shim-pack GISS C18 column were compared. Shim-pack GISS C18 column was capable of narrower chromatography peak and greater response. Compared to the isocratic elution method, the gradient one was able to separate the two analytes and the internal standard while reducing the residue. When seeking the pretreatment method, methanol and acetonitrile were used as protein precipitants for comparation, and the amount for precipitants was also investigated. The result showed that four-fold precipitation with acetonitrile was the way with highest analyte response, and best peak shape. 3.2 Method validation
3.2.1 Selectivity Representative chromatograms of blank volunteer plasmas, zero-point samples, LLOQ samples and volunteer plasma samples after administration were shown in Fig 3. The retention times of JJH201501, JJH201501-01 and fluoxetine were 1.17 min, 1.05 min and 1.15 min, respectively. In the chromatogram of blank plasma sample, the response intensity at different analyte retention time was < 20% of LLOQ while that at IS retention time was <5%. This result indicated that the analyte can be specifically determined and distinguished from plasma endogenous substances when applying the developed method in this study, which showed good selectivity. 3.2.2 Linearity and LLOQ The regression equations of the standard calibration curve were y=0.1227x+0.0066 for JJH201501 and y=0.0347x+0.0016 for JJH201501-01. R2 was 0.997 for JJH201501 and was 0.997 for JJH201501-01, indicating that calibration curve of JJH201501 was in good linearity from 0.2 to 50 ng/mL and the linear range for JJH201501-01 was from 0.4 to 100 ng/mL. Simultaneously, the RE of each concentration point was within 15%, and within 20% for LLOQ, in keeping with FDA guidelines for analytical methods. The lowest concentration points of the calibration curve were 0.2 ng/mL for JJH201501, 0.4 ng/mL for JJH201501-01, with the signal-to-noise ratio greater than 10. 3.2.3 Accuracy and precision The inter-, intra-run accuracy and precision results were shown in Table 2. The RE and CV within same concentration level in the intra-run investigation were less than 15%, which met the corresponding requirements. In the inter-run investigation, the RE and
CV in same concentration from three analytical batches were both less than 15%, in compliance with the requirements. The results indicated that the analytical method was accurate and possessed good repeatability between runs, which can be used for subsequent sample analysis. 3.2.4 Carryover For JJH201501, the response intensity in double blank sample was 16% of that in LLOQ. The response intensity of JJH201501-01 in double blank sample was 15% of that in LLOQ, while IS was 0.4%. It was indicated that the carryover of this method was acceptable. 3.2.5 Matrix effect and extraction recovery When preparing the pure solution QC samples, physiological saline was added into the samples to equal the solvent strength of pure solution sample and initial mobile phase. The results of matrix effect and extraction recovery investigation were shown in Table 3. In the investigation of matrix effect for JJH201501, the average IS-normalized MF (internal standard normalized matrix effect factors) in blank plasma and high fat matrix were both around 1, while in hemolyzed matrix was approximately 1.56. However, the average IS-normalized MF for JJH201501-01 in blank plasma and hemolyzed matrix were around 1.5, while in high fat matrix it was 1. The variation of the IS-normalized MF between different concentrations in same matrix was relatively small, indicating that the matrix effect was consistent among different concentration. In terms of different matrix, the result showed that blank plasma and high fat matrix did not have a large impact on response of JJH201501 while only high fat matrix had no obvious impact on
JJH201501-01. The average extraction recovery of the JJH201501 was 96.20%, 109.46% and 98.92% for LQC, MQC and HQC, respectively. The average extraction recovery of JJH201501-01 was 95.02%,109.60% and 100.88%, respectively. 3.2.6 Stability The results of the stability investigation were shown in Table 4 and Table 5. The RE (%) of LQC for JJH201501 was -2.4, 1.9, 7.9, 4.1 and 0.4 under conditions of -25℃ for 22 h, −20 ℃ for 6 days, −70 ℃ for 56 days, five freeze-thaw cycles and 8 ℃ for 24 h, respectively. The RE was -14, 1.9, 6.3, -5.8 and -2.2 respectively for HQC of JJH201501. The RE (%) of JJH201501-01 was 5.6, 2.4, 12.8, 12.1 and -4.5, respectively for LQC and was -7.6, 6.0, 5.9, 6.3 and -2.1, respectively for HQC. Both JJH201501 and JJH201501-01 were stable during this study, including both storage process and pretreatment period.
3.3 Application in a pharmacokinetic study The validated UPLC-MS/MS method was applied to analyze the plasma samples from JJH2015 pharmacokinetic study. The concentration-time profiles were showed in Fig 4. The JJH201501 concentration of most time points was in the linear range of the developed detection method, while there were few points below the lower limit of quantitation for JJH201501-01. Only the very beginning time points like 1 h, 2 h and the last points like 240 h of some subjects were below the LLOQ, which indicating the developed method was suitable for the detection of 10 mg/kg dose group. The linear range of this UPLC-MS/MS method would be applicable for the higher dose groups,
too. This analytical method was practicable for plasma pharmacokinetic studies throughout Phase I trial. The developed method can also be used for clinical monitor for plasma concentration of JJH201501 and its major metabolite JJH201501-01.
4. Conclusion In this study, a sensitive and rapid UPLC-MS/MS detection method and corresponding pre-treatment method were developed. A complete method validation was carried out. This method was be able to quantitatively determine the concentration of JJH201501 and its metabolite JJH201501-01 in human plasma simultaneously. The method validation results showed that the method met the requirements of guidelines for bioanalytical method proposed by the FDA in all aspects and can be applied in subsequent analysis of plasma biological samples for JJH201501. In addition, the newly developed method was successfully applied to the plasma drug concentration analysis of the JJH201501 in phase I clinical trial.
Acknowledgements This study was supported by “Double First-Class” initiative Innovation team project of China Pharmaceutical University (No. CPU2018GY29); National New Drug Innovation Program of China (No. 2017ZX09301004).
Reference [1] FDA, Drugs@FDA: FDA Approved Drug Products. [2] FDA, FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor). [3] B. Bang-Andersen, T. Ruhland, M. Jorgensen, G. Smith, K. Frederiksen, K.G. Jensen, H. Zhong, S.M. Nielsen, S. Hogg, A. Mork, T.B. Stensbol, Discovery of 1-[2(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder, J Med Chem, 54 (2011) 32063221. [4] A. Mørk, A. Pehrson, L.T. Brennum, S.M. Nielsen, H. Zhong, A.B. Lassen, S. Miller, L. Westrich, N.J. Boyle, C. Sánchez, C.W. Fischer, N. Liebenberg, G. Wegener, C. Bundgaard, S. Hogg, B. Bang-Andersen, T.B. Stensbøl, Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder, J Pharmacol Exp Ther, 340 (2012) 666. [5] C. Sanchez, K.E. Asin, F. Artigas, Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data, Pharmacol Ther, 145 (2015) 43-57. [6] C. Liguori, L. Ferini-Strambi, F. Izzi, L. Mari, N. Manfredi, A. D'Elia, N.B. Mercuri, F. Placidi, Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis, Brit J Clin Pharmaco, 85 (2019) 240-244. [7] M. Talmon, S. Rossi, A. Pastore, C.I. Cattaneo, S. Brunelleschi, L.G. Fresu, Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages, Br J Pharmacol, 175 (2018) 113-124. [8] J. Areberg, K.B. Petersen, G. Chen, H. Naik, Population pharmacokinetic metaanalysis of vortioxetine in healthy individuals, Basic Clin Pharmacol Toxicol, 115 (2014) 552-559. [9] G. Chen, A.-M. Højer, J. Areberg, G. Nomikos, Vortioxetine: clinical pharmacokinetics and drug interactions, Clin Pharmacokinet, 57 (2018) 673-686. [10] E.M. Russak, E.M. Bednarczyk, Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals, Ann Pharmacother, 53 (2019) 211-216. [11] D.S. Eisenberg, W. Kauzmann, The structure and properties of water, Oxford University Press, Oxford, 2005. [12] G.S. Timmins, Deuterated drugs: where are we now?, Expert Opin Ther Pat, 24 (2014) 1067-1075. [13] A. Mullard, FDA approves first deuterated drug, Nat Rev Drug Discov, 16 (2017) 305. [14] V. Uttamsingh, R. Gallegos, J.F. Liu, S.L. Harbeson, G.W. Bridson, C. Cheng, D.S. Wells, P.B. Graham, R. Zelle, R. Tung, Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine, J Pharmacol Exp Ther, 354 (2015) 43. [15] R. Sharma, T.J. Strelevitz, H. Gao, A.J. Clark, K. Schildknegt, R.S. Obach, S.L.
Ripp, D.K. Spracklin, L.M. Tremaine, A.D. Vaz, Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs, Drug Metab Dispos, 40 (2012) 625-634. [16] G.S. Timmins, Deuterated drugs; updates and obviousness analysis, Expert Opin Ther Pat, 27 (2017) 1353-1361. [17] S.L. Harbeson, A.J. Morgan, J.F. Liu, A.M. Aslanian, S. Nguyen, G.W. Bridson, C.L. Brummel, L. Wu, R.D. Tung, L. Pilja, V. Braman, V. Uttamsingh, Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development, J Pharmacol Exp Ther, 362 (2017) 359-367. [18] A. Mullard, Deuterated drugs draw heavier backing, Nat Rev Drug Discov, 15 (2016) 219.
Figures and legends Figure 1 Chemical structures of JJH201501(A), and JJH201501-01(B). Figure 2 MS/MS spectrum of JJH201501(A), and JJH201501-01(B). Figure 3 Representative MRM chromatograms of JJH201501, JJH201501-01 in human plasma: (A) Double blank sample; (B) Zero-point sample (Blank sample spiked with IS); (C) LLOQ sample; (D) sample from a subject 12 h postadministration of 10 mg JJH201501 tablet. Figure 4 Plasma concentration-time profiles of JJH201501 (A) and JJH20150101(B) in healthy volunteers (n=10) after oral administration of 10 mg JJH201501.
Figure 1 (A)
(B)
Figure 2 (A)
(B)
Figure 3 (A)
(B)
(to be continued)
(C)
(D)
Figure 4 (A)
(B)
Table 1 Optimized parameters on CE and DP of JJH201501, JJH201501-01 and IS. Analyte
CE
DP
JJH201501 JJH201501-01 fluoxetine
32 30 40
100 150 70
Table 2 Intra- and inter-run accuracy and precision result of quality control samples. (n=6) Intra-run Inter-run Concentration mean Analyte added concentration mean mean concentration mean CV(%) CV(%) (ng/mL) observed RE(%) observed (ng/mL) RE(%) (ng/mL) JJH201501 0.20 0.19 -5.1 3.14 0.19 0.20 0.21 0.28 8.04 0.60 0.63 5.2 3.41 0.63 0.63 0.63 4.84 2.76 4.00 3.94 -1.6 2.26 3.94 4.22 3.89 0.39 4.53 40.00 38.97 -2.6 2.29 38.97 40.39 36.70 -3.29 4.84 JJH2015010.40 0.45 12.1 9.2 0.45 0.40 0.441 7.44 8.35 01 1.20 1.29 7.8 2.59 1.29 1.14 1.233 1.89 5.71 8.00 7.66 -4.3 3.06 7.66 7.65 7.699 -4.16 2.76 80.00 79.95 -0.1 1.88 79.95 79.40 75.08 -2.32 4.21 Table 3 The extraction recovery and matrix effect of JJH201501 and JJH20150101 in human plasma (n = 6). Concentration Recovery(%) Analyte added (ng/mL) Mean CV(%) JJH201501 0.60 96.20 2.88 4.00 109.46 2.72 40.00 98.92 1.43 JJH2015011.20 95.02 2.58 01 8.00 109.60 2.31 80.00 100.88 2.60
blank plasma mean CV(%) 1.31 6.07 1.19 7.84 1.15 7.65 1.59 5.92 1.48 9.47 1.50 8.02
IS-normalized MF hemolyzed matrix mean CV(%) 1.62 8.20 1.58 8.99 1.49 5.83 1.72 4.19 1.57 3.23 1.53 1.39
high fat matrix mean CV(%) 1.11 6.56 1.20 5.93 1.22 5.71 0.98 1.99 1.16 1.10 1.14 1.27
Table 4 Stability of JJH201501 in human plasma under different conditions (n = 6). Concentration added (ng/mL) conditions
0.6（LQC）
40（HQC）
RE(%)
CV(%)
RE(%)
CV(%)
25℃ for 22h
-2.4
6.59
-14
4.92
−20 ℃ for 6 days
1.9
4.14
1.9
3.55
−70 ℃ for 56 days
7.9
8.88
6.3
3.37
five freeze-thaw cycles
4.1
4.08
-5.8
2.62
post-processed stability
0.4
3.9
-2.2
1.54
Table 5 Stability of JJH201501-01 in human plasma under different conditions (n = 6). Concentration added (ng/mL) conditions
1.2（LQC）
80（HQC）
RE(%)
CV(%)
RE(%)
CV(%)
25℃ for 22h
5.6
3.95
-7.6
6.28
−20 ℃ for 6 days
2.4
3.39
6.0
4.41
−70 ℃ for 56 days
12.8
9.18
5.9
2.24
five freeze-thaw cycles
12.1
2.78
6.3
3.52
post-processed stability
-4.5
2.13
-2.1
1.71
Highlights 1. A new UPLC-MS/MS method was developed for simultaneously determining deuterated vortioxetine (JJH201501) and its major metabolite (JJH201501-01) in human plasma. 2. The method was validated according to the guidelines of US FDA. 3. High throughput, sensitivity, and reliability were achieved. 4. The method was applied to a pharmacokinetic study of JJH201501 in healthy human volunteers and it is the first clinical pharmacokinetic study for JJH201501.
All other authors have read the manuscript and have agreed to submit it in its current form for consideration for publication in Journal of Chromatography B. The roles of all authors are as follows: Yingyue Yi: Writing- Original draft preparation, Methodology; Guanghui Ren: Investigation, Conceptualization; Ming Zheng: Investigation, Validation; Di Zhao: Resources; Ning Li: Resources, Data Curation; Xijng Chen: Supervision, Funding acquisition; Yang Lu: Writing - Review & Editing
S1570-0232(19)31662-9 https://doi.org/10.1016/j.jchromb.2019.121955 CHROMB 121955
To appear in:
Journal of Chromatography B
Received Date: Revised Date: Accepted Date:
14 November 2019 17 December 2019 19 December 2019
Please cite this article as: Y. Yi, G. Ren, M. Zheng, D. Zhao, N. Li, X. Chen, Y. Lu, Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers, Journal of Chromatography B (2019), doi: https://doi.org/10.1016/ j.jchromb.2019.121955
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2019 Published by Elsevier B.V.
Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers Yingyue Yia,#, Guanghui Rena,#, Ming Zhengc, Di Zhaoa, Ning Lib , Xijng Chena, *1, Yang Lua, *2 a
Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province 211198, China. b National Experimental Teaching Demonstration Center of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China. c School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 100 Kexue, Zhengzhou 450001, China #These authors contributed equally to the present work.
1
*Corresponding author at: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing 211198, China. E-mail address: [email protected]. 2 *Corresponding author at: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing 211198, China. E-mail address: [email protected]
Abstract JJH201501, a deuterated modification for multi-target antidepressant vortioxetine, is currently in phase I clinical trial. This study aimed to establish a sensitive and rapid UPLC-MS/MS method that was capable of simultaneously detecting JJH201501 and its major metabolite JJH201501-01 quantitatively in human plasma. The pretreatment was achieved by protein precipitation using 4-fold(v:v) acetonitrile with 0.05 ng/mL fluoxetine as internal standard precipitant. For method validation, the method was investigated in terms of the selectivity, inter- and intra-run precision and accuracy, matrix effect, extraction recovery and stability. The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively. The linear concentration range for JJH201501 and JJH201501-01 was 0.2 to 50 ng/mL and 0.4 to 100 ng/mL, respectively. The results showed that this method was in line with the guidelines for bioanalytical method proposed by FDA. In addition, the method was successfully applied to a plasma pharmacokinetic study of JJH201501 tablets in healthy volunteers which was part of the phase I trial.
Keywords: Deuterated modification; Vortioxetine; UPLC-MS/MS; Antidepressant; Healthy volunteers
1.Introduction Vortioxetine, a multi-target antidepressant drug, was approved by the FDA in 2013 [1], and changed its brand name from Brintellix to Trintellix in 2016 [2]. It was first synthesized and reported by Benny Bang-Andersen et al.[3]. Different from traditional antidepressants, vortioxetine exerted its efficiency through modulation of human serotonin receptors and inhibition of serotonin transporters (Ki=1.6 nM)[4]. Vortioxetine can increase the DA (dopamine), NA (noradrenaline) and 5-HT (5-hydroxytryptamine) levels in the medial prefrontal cortex and ventral hippocampus of rats. It is also effective in patients with major depressive disorder and can reduce the risk of relapse after remission of depression treatment
[5]
. Recent studies show that after treatment with
vortioxetine there is a significant alleviation for both insomnia and depressive symptoms in severe depressive disorder patients with insomnia[6]. In addition to antidepression, vortioxetine also exhibits an immunomodulatory activity[7]. In terms of pharmacokinetics, the two-compartment model fitted the concentration-time curve of vortioxetine in humans plasma to a great extent [8]. The average elimination half-life of vortioxetine in human is 66 h and the oral bioavailability reaches 75% [9].
Deuteration is defined as the process of replacing the hydrogen element in a molecule with deuterium. The strength of the C-2H bond is greater than that of the C-1H bond[10, 11]
, which results in the altered reaction rate of breaking C-2H bond during the
metabolism of the deuterated drug. The reaction rate might vary by a factor of 6 to 10 with the increase of deuterium-replacement[10]. Deuteration could reduce drug
elimination catalyzed by metabolic enzyme and the formation of toxic metabolites[12] via increasing the difficulty of decomposition of the C-2H band, thereby ameliorating some properties of the drug. In 2017, US FDA approved the first deuterated drugdeutetrabenazine from Teva Pharmaceuticals for the treatment of Huntington's disease [13]
. In addition, there are many other deuterated drugs in development stage. Compared
with the original drug, the deuterated modification could alter the drug metabolism and reduce toxicity[14-17].With the basis of the original drug, the development of deuterated drug possesses an advantage of convenience over new chemical entity [12].There will be a promising future for deuterated drugs[18].
JJH201501 was a deuterated modification of vortioxetine (structure shown in Fig 1). After intragastric administration in rats, JJH201501 was mainly excreted through feces and urine in forms of metabolites. JJH201501-01 was the main metabolite of JJH201501 in vivo and closely related to the metabolism of JJH201501. Currently, JJH201501 is in phase I clinical trial. This present study aimed to establish a sensitive and rapid UPLC-MS/MS (ultra-performance liquid chromatography-tandem mass spectrometry) determination method to quantify JJH201501 and JJH201501-01 simultaneously, which can provide assistance and reference for the follow-up investigation. 2. Material and method 2.1 Chemicals and reagents The reference standards of JJH201501 and JJH2015-01 were provided by Jiangsu
Jiberer Pharmaceutical Co., Ltd. (Jiangsu，China). Fluoxetine (used as internal standard, IS) was purchased from National Institutes of Food and Drug Control (Beijing, China). The HPLC-grade acetonitrile and methanol were purchased from Merck & Co., Inc (Germany). Ammonium acetate and formic acid of HPLC grade were purchased from Macklin Inc (Shanghai, China) and Shanghai Aladdin Bio-Chem Technology Co., LTD (Shanghai, China), respectively. Ultrapure water was purified by a Milli-Q Reagent Water System (Millipore, Bedford, MA, USA).
2.2 UPLC-MS/MS condition The separation of compounds was performed by ACQUITY UPLC system (Waters Corp., Milford, MA, USA), incorporating a Shim-pack GISS C18 column (2.1 mm × 50 mm, 1.9 μm). The column oven was set at 50℃. The gradient elution solvents were consisted of 0.1% formic acid aqueous solution (A) and acetonitrile (B), and the gradient procedure was set as follow: 0-0.5 min, 20%-95% B; 0.5-1.9 min, 95% B; 2.0– 3.0 min, 20% B. The flow rate was 0.50 mL/min. The total run time was 3 min. Quantification was performed by Triple QuadTM 6500+ Mass Spectrometer with Analyst 1.7.1 software package (AB SCIEX LLC., Redwood City, CA, USA), using positive-mode electrospray ionization (ESI) interface. Multiple-reaction monitoringmode was applied. Quantification was achieved by transitions of m/z 302.2→149.9, m/z 329.1→286.1 and m/z 310.1→44 for JJH201501, JJH201501-01 and fluoxetine (IS), respectively. The optimal instrument conditions were as follows: curtain gas, gas 1 and gas 2 (nitrogen) were 40, 55 and 55 psi respectively; collision gas was 8 psi; dwell
time was 200 ms; source temperature was 600 ℃; Ion spray voltage was 5500 V. Declustering potentials (DP) and collision energy (CE) were shown in Table 1.
2.3 Sample preparation 2.3.1 Preparation of stock and working solution Stock solutions of JJH201501, JJH2015-01, fluoxetine (IS) were separately prepared by dissolving the reference standard in methanol at the concentration of 1.0 mg/mL and stored at 2-8℃. Mixed standard working solutions of JJH201501 and JJH2015-01 were prepared by diluting the mixed solution 1 (JJH201501:1000 ng/mL; JJH2015-01:2000 ng/mL) with methanol to the JJH201501 concentrations of 4, 10, 20, 40, 100, 200, 400 ng/mL and JJH201501-01 concentrations of 8, 20, 40, 80, 200, 400, 800 ng/mL. The mixed quality control (QC) solutions were prepared from the mixed solution with same concentration as mixed solution 1, in which JJH201501 concentrations were 4 (LLOQ, lower limit of quantitation), 12 (LQC, low quality control), 80 (MQC, medium quality control), and 800 (HQC, high quality control) ng/mL and JJH201501-01 concentrations were 8, 24, 160, 1600 ng/mL, respectively. Fluoxetine (IS) working solution was prepared by diluting the stock solution with acetonitrile to 1 ng/mL. All working solutions were stored at 2-8℃.
2.3.2 Preparation of calibration and QC samples Calibration and QC samples were prepared by mixing 20 μL of corresponding working
solutions with 380 μL blank human plasma. The final calibration curve included following concentration points: 0.2, 0.5, 1, 2, 5, 10, 20, 50 ng/mL for JJH201501 and 0.4, 1, 2, 4, 10, 20, 40, 100 ng/mL for JJH2015-01. Mixed QC samples were consisted of LLOQ, LQC, MQC and HQC samples. The respective JJH201501 concentration was 0.2, 0.6, 4 and 40 ng/mL. The IS working solutions were diluted with 19 folds (v:v) acetonitrile to get internal standard precipitant.
2.3.3 Sample preparation 200 μL of internal standard precipitant was added into 50 μL thawed plasma samples for protein precipitation, and then the sample was vortex-mixed for 5 min. Subsequently, the fully blended mixtures were centrifuged at 18000 g for 10 min and 80 μL of the supernatant was transferred into auto-sampler vial, 1 μL of which was injected into the UPLC-MS/MS system for analysis.
2.4 Method validation The analytical method was validated in accordance with the guidelines proposed by US FDA in the following aspects: selectivity, linearity and lower limit of quantification, accuracy and precision, carryover, matrix effect and extraction recovery, stability.
2.4.1 Selectivity Blank human plasma from six different volunteers was employed to validate the selectivity of the method to see if there was any background interference for analytes
and IS. Simultaneously, LLOQ (lower limit of quantification) samples, the lowest point of the calibration curve whose signal-to-noise ratio (S/N) >10, was prepared as control. According to the guideline, the response intensity appearing at the retention time of analytes and IS should be less than 20% and 5% of response intensity in LLOQ, separately.
2.4.2 Linearity and LLOQ Linearity of the method was evaluated, based on the standard calibration curve. A batch of standard calibration curve samples were consisted of double blank (blank plasma with pure precipitant, acetonitrile in this case), zero-point sample (blank plasma with internal standard precipitant) and eight gradient calibration samples. Double calibration standard curves were employed which were placed respectively at the beginning and end of an analytical batch. To obtain the calibration curve, firstly the peak area ratios (y) of each analyte to IS was plotted against the theoretical concentrations (x) and then the weighted least-squares linear regression(1/x2) was made to get the regression line and equation. The sensitivity investigation was based on lower limit of quantitation (LLOQ), which should be within ± 20% for accuracy (relative error, RE, %), while RE of other points on the standard calibration curve should be within ± 15% for accuracy.
2.4.3 Accuracy and precision The intra- and inter-run accuracy and precision were evaluated as the variation of QC
samples. For investigation of intra run accuracy and precision, six replicate QC samples at each concentration, namely, LLOQ, LQC, MQC, HQC (n=6) were analyzed in the same analytical batch while the inter-run counterpart was evaluated between three analytical batch. The accuracy was calculated as the RE of each sample and the precision was determined as RSD of six replicates at the same concentration. According to the guideline, the intra- and inter-run accuracy was supposed to be within ± 15% while that of LLOQ should be within ± 20%. The precision should be within ± 15% (for LLOQ, within ± 20%). 2.4.4 Carryover Carryover was evaluated by residual response arose from the upper limit of quantification (ULOQ), the highest point on the calibration curve. There was a double blank sample after injection of ULOQ in the same run to investigate the carryover. The response intensity in the blank sample was not supposed to exceed 20% of the LLOQ of the analytes, and 5% of the IS. 2.4.5 Matrix effect and extraction recovery The matrix effect and extraction recovery were evaluated by comparing pure solution QC samples, unextracted QC samples and post-extracted QC samples. Pure solution QC samples (n=6) were consisted of 10 μL QC solution, 40 μL IS working solution, 190 μL physiological saline and 760 μL acetonitrile while unextracted QC samples (n=6) were made by combination of 10 μL QC solutions, 40 μL IS working solution and 950 μL post-extracted matrix. Three different types of matrix were investigated, including blank plasma, hemolyzed matrix and high fat matrix. Post-extracted QC samples (n=6)
were prepared by the method shown in 2.3.3. 2.4.6 Stability The stability of the analytes plasma samples was evaluated by LQC (n=6) and HQC (n=6) samples placed under different conditions: room temperature (25℃) for 22 h; −20 ℃ for 6 days; −70 ℃ for 56 days; five freeze (−70℃)-thaw (25℃) cycles; and processedsamples at auto-sampler vials (8 ℃) for 24 h. The RE of plasma samples under different condition to fresh plasma sample should be within 15%, and the CV (%) should be below 15%.
2.5 Application in the JJH201501 pharmacokinetic study The clinical trial was approved by the China Food and Drug Administration (No. 2018L02861). The whole study was carried out in accordance with the chemical drug clinical pharmacokinetic study technical guidelines of China and the Declaration of Helsinki. Before the study, the Informed Consent Form was reviewed and signed by every enrolled subject.
Twelve adult healthy volunteers were enrolled, including 6 males and 6 females. They were randomly assigned into JJH201501 group (10 volunteers) and placebo group (2 volunteers). All volunteers were aged between 18–45 years; the male volunteers were weighed beyond 50 kg, while the female volunteers were beyond 45 kg; the body mass indexes (BMI) of all volunteers were between 18-26 kg/m2. Volunteers were administrated with JJH201501 tablet under fasting state at an oral dose
of 10 mg/kg. Blood samples were collected 1 h pre-administration and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 240 h post-administration. Blood samples were placed in heparinized centrifugal tubes, subsequently centrifuged at 3075 g for 10 min at 4 °C (blood sample collection was completed within 1 h), and the separated plasma was stored at -70 ± 10 °C before analysis. 3. Results and discussion 3.1. Method development To choose the internal standard, several compounds including vortioxetine-D8 and fluoxetine were investigated. Vortioxetine-D8 showed interference to the peak of JJH201501. The structure of fluoxetine was similar to that of JJH201501 and its retention time is close to JJH201501 without any inference to the peak of JJH201501. Thus, fluoxetine was selected as the internal standard. In the process of establishing chromatography method, the ACQUITY UPLC
®
BEH
C18 column and Shim-pack GISS C18 column were compared. Shim-pack GISS C18 column was capable of narrower chromatography peak and greater response. Compared to the isocratic elution method, the gradient one was able to separate the two analytes and the internal standard while reducing the residue. When seeking the pretreatment method, methanol and acetonitrile were used as protein precipitants for comparation, and the amount for precipitants was also investigated. The result showed that four-fold precipitation with acetonitrile was the way with highest analyte response, and best peak shape. 3.2 Method validation
3.2.1 Selectivity Representative chromatograms of blank volunteer plasmas, zero-point samples, LLOQ samples and volunteer plasma samples after administration were shown in Fig 3. The retention times of JJH201501, JJH201501-01 and fluoxetine were 1.17 min, 1.05 min and 1.15 min, respectively. In the chromatogram of blank plasma sample, the response intensity at different analyte retention time was < 20% of LLOQ while that at IS retention time was <5%. This result indicated that the analyte can be specifically determined and distinguished from plasma endogenous substances when applying the developed method in this study, which showed good selectivity. 3.2.2 Linearity and LLOQ The regression equations of the standard calibration curve were y=0.1227x+0.0066 for JJH201501 and y=0.0347x+0.0016 for JJH201501-01. R2 was 0.997 for JJH201501 and was 0.997 for JJH201501-01, indicating that calibration curve of JJH201501 was in good linearity from 0.2 to 50 ng/mL and the linear range for JJH201501-01 was from 0.4 to 100 ng/mL. Simultaneously, the RE of each concentration point was within 15%, and within 20% for LLOQ, in keeping with FDA guidelines for analytical methods. The lowest concentration points of the calibration curve were 0.2 ng/mL for JJH201501, 0.4 ng/mL for JJH201501-01, with the signal-to-noise ratio greater than 10. 3.2.3 Accuracy and precision The inter-, intra-run accuracy and precision results were shown in Table 2. The RE and CV within same concentration level in the intra-run investigation were less than 15%, which met the corresponding requirements. In the inter-run investigation, the RE and
CV in same concentration from three analytical batches were both less than 15%, in compliance with the requirements. The results indicated that the analytical method was accurate and possessed good repeatability between runs, which can be used for subsequent sample analysis. 3.2.4 Carryover For JJH201501, the response intensity in double blank sample was 16% of that in LLOQ. The response intensity of JJH201501-01 in double blank sample was 15% of that in LLOQ, while IS was 0.4%. It was indicated that the carryover of this method was acceptable. 3.2.5 Matrix effect and extraction recovery When preparing the pure solution QC samples, physiological saline was added into the samples to equal the solvent strength of pure solution sample and initial mobile phase. The results of matrix effect and extraction recovery investigation were shown in Table 3. In the investigation of matrix effect for JJH201501, the average IS-normalized MF (internal standard normalized matrix effect factors) in blank plasma and high fat matrix were both around 1, while in hemolyzed matrix was approximately 1.56. However, the average IS-normalized MF for JJH201501-01 in blank plasma and hemolyzed matrix were around 1.5, while in high fat matrix it was 1. The variation of the IS-normalized MF between different concentrations in same matrix was relatively small, indicating that the matrix effect was consistent among different concentration. In terms of different matrix, the result showed that blank plasma and high fat matrix did not have a large impact on response of JJH201501 while only high fat matrix had no obvious impact on
JJH201501-01. The average extraction recovery of the JJH201501 was 96.20%, 109.46% and 98.92% for LQC, MQC and HQC, respectively. The average extraction recovery of JJH201501-01 was 95.02%,109.60% and 100.88%, respectively. 3.2.6 Stability The results of the stability investigation were shown in Table 4 and Table 5. The RE (%) of LQC for JJH201501 was -2.4, 1.9, 7.9, 4.1 and 0.4 under conditions of -25℃ for 22 h, −20 ℃ for 6 days, −70 ℃ for 56 days, five freeze-thaw cycles and 8 ℃ for 24 h, respectively. The RE was -14, 1.9, 6.3, -5.8 and -2.2 respectively for HQC of JJH201501. The RE (%) of JJH201501-01 was 5.6, 2.4, 12.8, 12.1 and -4.5, respectively for LQC and was -7.6, 6.0, 5.9, 6.3 and -2.1, respectively for HQC. Both JJH201501 and JJH201501-01 were stable during this study, including both storage process and pretreatment period.
3.3 Application in a pharmacokinetic study The validated UPLC-MS/MS method was applied to analyze the plasma samples from JJH2015 pharmacokinetic study. The concentration-time profiles were showed in Fig 4. The JJH201501 concentration of most time points was in the linear range of the developed detection method, while there were few points below the lower limit of quantitation for JJH201501-01. Only the very beginning time points like 1 h, 2 h and the last points like 240 h of some subjects were below the LLOQ, which indicating the developed method was suitable for the detection of 10 mg/kg dose group. The linear range of this UPLC-MS/MS method would be applicable for the higher dose groups,
too. This analytical method was practicable for plasma pharmacokinetic studies throughout Phase I trial. The developed method can also be used for clinical monitor for plasma concentration of JJH201501 and its major metabolite JJH201501-01.
4. Conclusion In this study, a sensitive and rapid UPLC-MS/MS detection method and corresponding pre-treatment method were developed. A complete method validation was carried out. This method was be able to quantitatively determine the concentration of JJH201501 and its metabolite JJH201501-01 in human plasma simultaneously. The method validation results showed that the method met the requirements of guidelines for bioanalytical method proposed by the FDA in all aspects and can be applied in subsequent analysis of plasma biological samples for JJH201501. In addition, the newly developed method was successfully applied to the plasma drug concentration analysis of the JJH201501 in phase I clinical trial.
Acknowledgements This study was supported by “Double First-Class” initiative Innovation team project of China Pharmaceutical University (No. CPU2018GY29); National New Drug Innovation Program of China (No. 2017ZX09301004).
Reference [1] FDA, Drugs@FDA: FDA Approved Drug Products. [2] FDA, FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor). [3] B. Bang-Andersen, T. Ruhland, M. Jorgensen, G. Smith, K. Frederiksen, K.G. Jensen, H. Zhong, S.M. Nielsen, S. Hogg, A. Mork, T.B. Stensbol, Discovery of 1-[2(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder, J Med Chem, 54 (2011) 32063221. [4] A. Mørk, A. Pehrson, L.T. Brennum, S.M. Nielsen, H. Zhong, A.B. Lassen, S. Miller, L. Westrich, N.J. Boyle, C. Sánchez, C.W. Fischer, N. Liebenberg, G. Wegener, C. Bundgaard, S. Hogg, B. Bang-Andersen, T.B. Stensbøl, Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder, J Pharmacol Exp Ther, 340 (2012) 666. [5] C. Sanchez, K.E. Asin, F. Artigas, Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data, Pharmacol Ther, 145 (2015) 43-57. [6] C. Liguori, L. Ferini-Strambi, F. Izzi, L. Mari, N. Manfredi, A. D'Elia, N.B. Mercuri, F. Placidi, Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis, Brit J Clin Pharmaco, 85 (2019) 240-244. [7] M. Talmon, S. Rossi, A. Pastore, C.I. Cattaneo, S. Brunelleschi, L.G. Fresu, Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages, Br J Pharmacol, 175 (2018) 113-124. [8] J. Areberg, K.B. Petersen, G. Chen, H. Naik, Population pharmacokinetic metaanalysis of vortioxetine in healthy individuals, Basic Clin Pharmacol Toxicol, 115 (2014) 552-559. [9] G. Chen, A.-M. Højer, J. Areberg, G. Nomikos, Vortioxetine: clinical pharmacokinetics and drug interactions, Clin Pharmacokinet, 57 (2018) 673-686. [10] E.M. Russak, E.M. Bednarczyk, Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals, Ann Pharmacother, 53 (2019) 211-216. [11] D.S. Eisenberg, W. Kauzmann, The structure and properties of water, Oxford University Press, Oxford, 2005. [12] G.S. Timmins, Deuterated drugs: where are we now?, Expert Opin Ther Pat, 24 (2014) 1067-1075. [13] A. Mullard, FDA approves first deuterated drug, Nat Rev Drug Discov, 16 (2017) 305. [14] V. Uttamsingh, R. Gallegos, J.F. Liu, S.L. Harbeson, G.W. Bridson, C. Cheng, D.S. Wells, P.B. Graham, R. Zelle, R. Tung, Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine, J Pharmacol Exp Ther, 354 (2015) 43. [15] R. Sharma, T.J. Strelevitz, H. Gao, A.J. Clark, K. Schildknegt, R.S. Obach, S.L.
Ripp, D.K. Spracklin, L.M. Tremaine, A.D. Vaz, Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs, Drug Metab Dispos, 40 (2012) 625-634. [16] G.S. Timmins, Deuterated drugs; updates and obviousness analysis, Expert Opin Ther Pat, 27 (2017) 1353-1361. [17] S.L. Harbeson, A.J. Morgan, J.F. Liu, A.M. Aslanian, S. Nguyen, G.W. Bridson, C.L. Brummel, L. Wu, R.D. Tung, L. Pilja, V. Braman, V. Uttamsingh, Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development, J Pharmacol Exp Ther, 362 (2017) 359-367. [18] A. Mullard, Deuterated drugs draw heavier backing, Nat Rev Drug Discov, 15 (2016) 219.
Figures and legends Figure 1 Chemical structures of JJH201501(A), and JJH201501-01(B). Figure 2 MS/MS spectrum of JJH201501(A), and JJH201501-01(B). Figure 3 Representative MRM chromatograms of JJH201501, JJH201501-01 in human plasma: (A) Double blank sample; (B) Zero-point sample (Blank sample spiked with IS); (C) LLOQ sample; (D) sample from a subject 12 h postadministration of 10 mg JJH201501 tablet. Figure 4 Plasma concentration-time profiles of JJH201501 (A) and JJH20150101(B) in healthy volunteers (n=10) after oral administration of 10 mg JJH201501.
Figure 1 (A)
(B)
Figure 2 (A)
(B)
Figure 3 (A)
(B)
(to be continued)
(C)
(D)
Figure 4 (A)
(B)
Table 1 Optimized parameters on CE and DP of JJH201501, JJH201501-01 and IS. Analyte
CE
DP
JJH201501 JJH201501-01 fluoxetine
32 30 40
100 150 70
Table 2 Intra- and inter-run accuracy and precision result of quality control samples. (n=6) Intra-run Inter-run Concentration mean Analyte added concentration mean mean concentration mean CV(%) CV(%) (ng/mL) observed RE(%) observed (ng/mL) RE(%) (ng/mL) JJH201501 0.20 0.19 -5.1 3.14 0.19 0.20 0.21 0.28 8.04 0.60 0.63 5.2 3.41 0.63 0.63 0.63 4.84 2.76 4.00 3.94 -1.6 2.26 3.94 4.22 3.89 0.39 4.53 40.00 38.97 -2.6 2.29 38.97 40.39 36.70 -3.29 4.84 JJH2015010.40 0.45 12.1 9.2 0.45 0.40 0.441 7.44 8.35 01 1.20 1.29 7.8 2.59 1.29 1.14 1.233 1.89 5.71 8.00 7.66 -4.3 3.06 7.66 7.65 7.699 -4.16 2.76 80.00 79.95 -0.1 1.88 79.95 79.40 75.08 -2.32 4.21 Table 3 The extraction recovery and matrix effect of JJH201501 and JJH20150101 in human plasma (n = 6). Concentration Recovery(%) Analyte added (ng/mL) Mean CV(%) JJH201501 0.60 96.20 2.88 4.00 109.46 2.72 40.00 98.92 1.43 JJH2015011.20 95.02 2.58 01 8.00 109.60 2.31 80.00 100.88 2.60
blank plasma mean CV(%) 1.31 6.07 1.19 7.84 1.15 7.65 1.59 5.92 1.48 9.47 1.50 8.02
IS-normalized MF hemolyzed matrix mean CV(%) 1.62 8.20 1.58 8.99 1.49 5.83 1.72 4.19 1.57 3.23 1.53 1.39
high fat matrix mean CV(%) 1.11 6.56 1.20 5.93 1.22 5.71 0.98 1.99 1.16 1.10 1.14 1.27
Table 4 Stability of JJH201501 in human plasma under different conditions (n = 6). Concentration added (ng/mL) conditions
0.6（LQC）
40（HQC）
RE(%)
CV(%)
RE(%)
CV(%)
25℃ for 22h
-2.4
6.59
-14
4.92
−20 ℃ for 6 days
1.9
4.14
1.9
3.55
−70 ℃ for 56 days
7.9
8.88
6.3
3.37
five freeze-thaw cycles
4.1
4.08
-5.8
2.62
post-processed stability
0.4
3.9
-2.2
1.54
Table 5 Stability of JJH201501-01 in human plasma under different conditions (n = 6). Concentration added (ng/mL) conditions
1.2（LQC）
80（HQC）
RE(%)
CV(%)
RE(%)
CV(%)
25℃ for 22h
5.6
3.95
-7.6
6.28
−20 ℃ for 6 days
2.4
3.39
6.0
4.41
−70 ℃ for 56 days
12.8
9.18
5.9
2.24
five freeze-thaw cycles
12.1
2.78
6.3
3.52
post-processed stability
-4.5
2.13
-2.1
1.71
Highlights 1. A new UPLC-MS/MS method was developed for simultaneously determining deuterated vortioxetine (JJH201501) and its major metabolite (JJH201501-01) in human plasma. 2. The method was validated according to the guidelines of US FDA. 3. High throughput, sensitivity, and reliability were achieved. 4. The method was applied to a pharmacokinetic study of JJH201501 in healthy human volunteers and it is the first clinical pharmacokinetic study for JJH201501.
All other authors have read the manuscript and have agreed to submit it in its current form for consideration for publication in Journal of Chromatography B. The roles of all authors are as follows: Yingyue Yi: Writing- Original draft preparation, Methodology; Guanghui Ren: Investigation, Conceptualization; Ming Zheng: Investigation, Validation; Di Zhao: Resources; Ning Li: Resources, Data Curation; Xijng Chen: Supervision, Funding acquisition; Yang Lu: Writing - Review & Editing